Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers

• Outros Autores: Kayser, Veysel (Editor)
• Formato: Recurso Electrónico Capítulo de Livro
• Idioma: inglês
• Publicado em: Basel MDPI - Multidisciplinary Digital Publishing Institute 2022
• Assuntos: Medicine; Pharmaceutical industries; monoclonal antibody; NSCLC; immunotherapy; ELISA; pharmacokinetics; pharmacogenetics; anti-PD-1 monoclonal antibodies; anti-acetylcholine receptor (AChR) antibody; B cell; immune checkpoint blockade; immune-related adverse events (irAEs); myasthenia gravis (MG); non-small-cell lung cancer (NSCLC); nivolumab; programmed cell death ligand 1 (PD-L1); T cell; tetraspanins; cancer; Tspan8; radioimmunotherapy; immune-checkpoint inhibitors; LDH; biomarkers; Ang-2; antiangiogenic therapy; in vivo imaging; radio- and chemotherapy; VEGF-A; cancer therapy; neovascularization; angiogenesis; tumor microenvironment; colorectal cancer; antibody; NK cells; ADCC; CD133; prominin-1; gold nanoparticles; antibody-drug conjugates; cell penetrating peptide; HIV-1 TAT; active-targeting; targeted delivery; trastuzumab; MMAE; valine-citrulline; affibody; drug conjugates; hepatic uptake; DM1; dermatooncology; immune checkpoints; monoclonal antibodies; passive immunotherapy; canine B-cell lymphoma; DLA-DR; HLA-DR; antibody-drug conjugate; ADC; methotrexate; tumor immunity; combination therapy; multiple myeloma (MM); monoclonal antibodies (mAbs); antibody products; B cell maturation antigens (BCMAs); bispecific T cell engagers (BiTEs®); checkpoint inhibitors 1; protein structure 2; pharmacokinetics 3; drug optimization 4; HER2-positive breast cancer; metastatic disease; neoadjuvant and adjuvant therapy; targeted therapy; acute myeloid leukemia; CD123; IL3RA; kinesin spindle protein inhibitor
• Acesso em linha: DOAB: download the publication; DOAB: description of the publication

The book broadly deals with therapeutic monoclonal antibodies (mAbs) and various relevant topics, including different antibody formats such as Antibody-Drug Conjugates (ADC), bispecifics, nanoparticle-based mAbs and HER2+ cancers, immune checkpoint inhibitors and other closely related topics. Each p...